Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright

HC Wainwright restated their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT - Free Report) in a report published on Thursday,Benzinga reports. The brokerage currently has a $75.00 price objective on the biotechnology company's stock.

A number of other equities research analysts also recently issued reports on SRPT. Royal Bank of Canada reiterated an "outperform" rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Needham & Company LLC decreased their price objective on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a "buy" rating on the stock in a research note on Wednesday, November 27th. Evercore ISI lowered their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald raised Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and raised their target price for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Jefferies Financial Group began coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a "buy" rating and a $165.00 price target for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $178.71.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded down $0.78 during trading on Thursday, reaching $119.47. 1,031,128 shares of the company traded hands, compared to its average volume of 1,217,208. The firm has a market capitalization of $11.41 billion, a PE ratio of 95.58 and a beta of 0.77. Sarepta Therapeutics has a 52 week low of $89.92 and a 52 week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company's 50 day moving average is $123.41 and its two-hundred day moving average is $131.36.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company's stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm's stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC grew its holdings in shares of Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Wellington Management Group LLP boosted its position in Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Geode Capital Management LLC grew its stake in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Jacobs Levy Equity Management Inc. increased its position in shares of Sarepta Therapeutics by 9.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company's stock valued at $94,148,000 after purchasing an additional 63,437 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its stake in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company's stock worth $101,858,000 after purchasing an additional 37,940 shares during the period. Institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.